Santosh Kesari is a Neurology physician affiliated with Santa Monica College. OpenAlex indexes 829 publications with 36,003 citations (h-index 78); ClinicalTrials.gov lists 13 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2811 Wilshire Blvd Ste 790
Santa Monica, CA 904034805
Telephone
310-870-7260Provider last certified this registry record 2 Dec 2025.
Clinical trials
- A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
Sponsor: Stemedica Cell Technologies, Inc.
- Pemetrexed for the Treatment of Chordoma
Sponsor: Saint John's Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
43 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Jubilant Therapeutics IncProgram year20251 payment$15,000openpaymentsdata.cms.gov ↗
- Caris MPI, Inc.Program year20252 payments
- Axsome Therapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2009–2017 per NIH RePORTER. The latest:
- Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma
Saint John'S Cancer Institute
FY2017$296,167R01FD005077 - Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma
Saint John'S Cancer Institute
FY2016$400,000R01FD005077 - Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma
University of California, San Diego
FY2015$400,000R01FD005077
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”